BioSpace News Archive

Adagene Inc. today announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021.

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints).

Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9.

Zynerba Pharmaceuticals , Inc. today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021.

MediWound Ltd. (Nasdaq: MDWD) (the “Company”), today announced it has completed patient enrollment in its U.S. Phase 2 adaptive design clinical study evaluating the safety and efficacy of EscharEx® in debridement of venous leg ulcers (VLUs) compared to gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement).

Gritstone bio, Inc. and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of their agreement in order to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant.

SCYNEXIS, Inc. (NASDAQ: SCYX), today announced initiation of a global Phase 3 study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a step-down therapy for patients with invasive candidiasis and/or candidemia following intravenous (IV) echinocandin therapy in the hospital compared to currently-available outpatient therapies.

Autolus Therapeutics plc today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.

ASLAN Pharmaceuticals today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials.

GH Research PLC today reported the successful outcome of the Phase 2 part of a Phase 1/2 clinical trial of GH001, an inhalable 5-MeO-DMT product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-102).